Iterum Therapeutics (ITRM) Competitors $0.68 +0.00 (+0.37%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. HURA, CGEN, GNLX, MGNX, ZNTL, PLX, BHST, IKT, SKYE, and TARAShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include TuHURA Biosciences (HURA), Compugen (CGEN), Genelux (GNLX), MacroGenics (MGNX), Zentalis Pharmaceuticals (ZNTL), Protalix BioTherapeutics (PLX), BioHarvest Sciences (BHST), Inhibikase Therapeutics (IKT), Skye Bioscience (SKYE), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Its Competitors TuHURA Biosciences Compugen Genelux MacroGenics Zentalis Pharmaceuticals Protalix BioTherapeutics BioHarvest Sciences Inhibikase Therapeutics Skye Bioscience Protara Therapeutics Iterum Therapeutics (NASDAQ:ITRM) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings. Do insiders and institutionals hold more shares of ITRM or HURA? 9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 2.4% of Iterum Therapeutics shares are held by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation and earnings, ITRM or HURA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$0.85-0.81TuHURA BiosciencesN/AN/A-$21.68MN/AN/A Do analysts prefer ITRM or HURA? Iterum Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 1,213.87%. TuHURA Biosciences has a consensus target price of $12.67, suggesting a potential upside of 410.75%. Given Iterum Therapeutics' higher possible upside, research analysts plainly believe Iterum Therapeutics is more favorable than TuHURA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Does the media favor ITRM or HURA? In the previous week, Iterum Therapeutics and Iterum Therapeutics both had 2 articles in the media. Iterum Therapeutics' average media sentiment score of 1.45 beat TuHURA Biosciences' score of 1.08 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Iterum Therapeutics Positive TuHURA Biosciences Positive Which has more volatility and risk, ITRM or HURA? Iterum Therapeutics has a beta of 3.04, suggesting that its share price is 204% more volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Is ITRM or HURA more profitable? Iterum Therapeutics' return on equity of 0.00% beat TuHURA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -65.01% TuHURA Biosciences N/A -248.79%-150.83% SummaryIterum Therapeutics beats TuHURA Biosciences on 7 of the 11 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.45M$2.54B$5.76B$10.27BDividend YieldN/A57.24%5.73%4.60%P/E Ratio-0.8123.5275.4426.24Price / SalesN/A545.32457.8390.99Price / CashN/A27.5625.8129.91Price / Book-4.575.4213.236.30Net Income-$24.77M$32.95M$3.29B$270.76M7 Day Performance3.74%1.12%0.93%3.03%1 Month Performance-20.63%5.26%5.14%6.38%1 Year Performance-37.16%-1.48%74.06%26.35% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics3.0052 of 5 stars$0.69+0.4%$9.00+1,213.9%-37.4%$32.45MN/A-0.8110Positive NewsShort Interest ↓Gap UpHURATuHURA Biosciences1.7465 of 5 stars$2.52-1.2%$12.67+402.6%N/A$127.62MN/A0.00N/ACGENCompugen1.7177 of 5 stars$1.45+1.4%$4.00+175.9%-32.0%$127.61M$27.86M-6.5970GNLXGenelux1.573 of 5 stars$3.56+5.6%$20.33+471.2%+61.9%$127.30M$10K-4.1410High Trading VolumeMGNXMacroGenics4.4429 of 5 stars$1.76-12.0%$3.60+104.5%-57.0%$126.41M$149.96M-3.09430ZNTLZentalis Pharmaceuticals2.0074 of 5 stars$1.63-6.9%$8.20+403.1%-54.0%$126.24M$67.43M-0.72160Positive NewsPLXProtalix BioTherapeutics2.3305 of 5 stars$1.58+2.6%$15.00+849.4%+72.4%$125.98M$61.95M-12.15200High Trading VolumeBHSTBioHarvest Sciences2.4325 of 5 stars$7.14-5.9%$13.67+91.4%N/A$124.67M$25.19M-10.20N/AGap UpIKTInhibikase Therapeutics0.0063 of 5 stars$1.66-0.6%N/AN/A$124.44M$260K0.006SKYESkye Bioscience2.0558 of 5 stars$4.12+3.0%$15.50+276.2%-29.2%$123.95MN/A-3.8911Gap UpTARAProtara Therapeutics1.7367 of 5 stars$3.07-2.5%$19.60+538.4%+67.0%$121.53MN/A-1.9030Positive News Related Companies and Tools Related Companies TuHURA Biosciences Alternatives Compugen Alternatives Genelux Alternatives MacroGenics Alternatives Zentalis Pharmaceuticals Alternatives Protalix BioTherapeutics Alternatives BioHarvest Sciences Alternatives Inhibikase Therapeutics Alternatives Skye Bioscience Alternatives Protara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITRM Stock Alerts